Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $219M (up 32.4% year over year) with net income of −$58M.
Q2 2026 key financials · XBRL
- Revenue
- $219M
- +32.4% YoY · +5.5% QoQ
- Net income
- −$58M
- −359.4% YoY · −2445.6% QoQ
- Operating margin
- -26.5%
- EPS (diluted)
- −$1.01
- −352.5% YoY · −2425.0% QoQ
Source: XBRL data from the SUPERNUS PHARMACEUTICALS, INC. (SUPN) Q2 2026 10-Q on SEC EDGAR. USD.
SUPERNUS PHARMACEUTICALS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $219.1M, up 32% YoY from $165.5M, driven by ZURZUVAE collaboration revenue of $35.4M
- Best product performer: ONAPGO sales $13.5M, up 745% YoY; worst: Other sales $1.9M, down 71%
- Qelbree sales $89.2M, up 15% YoY; GOCOVRI sales $37.5M, up 2%
- Near-term headwind: ONAPGO supplier constraints; second supplier expected in 2027 pending FDA approval
- SPN-443 Phase 1 SAD and MAD studies planned for the second half of 2026
Risk Factors
- No material changes stated from the 2025 Form 10-K or June 30, 2026 Form 10-Q
- Business and financial-condition risk from adverse events potentially reducing common-stock market value
- Acquisition-related execution risk following April 1, 2026 Navitor asset purchase agreement
- Insider-trading compliance exposure from director’s June 15, 2026 Rule 10b5-1 plan covering 5,000 sales
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SUPERNUS PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.